Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells

British Journal of Haematology

Volumn 130, Issue 6, 2005, Pages 912-925

  Morgan, Michael A ^a   Sebil, Tarkan ^a   Aydilek, Erdem ^a   Peest, Dietrich ^a   Ganser, Arnold ^a   Reuter, Christoph W M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Farnesyltransferase inhibitors; Geranylgeranyltransferase I inhibitors; Lovastatin; Multiple myeloma; RAS signalling

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; GERANYLGERANYLTRANSFERASE INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; K RAS PROTEIN; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHO FACTOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; TRANSFERASE;

ADULT; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE RAS; PLASMA CELL LEUKEMIA; PRENYLATION; PRIORITY JOURNAL; CELL CULTURE; CELL DEATH; CELL DIVISION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ADULT; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL DIVISION; CELL MOVEMENT; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; LOVASTATIN; MAP KINASE SIGNALING SYSTEM; MULTIPLE MYELOMA; PROTEIN ISOPRENYLATION; RAS PROTEINS; TUMOR CELLS, CULTURED;

EID: 27244450832     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05696.x     Document Type: Article

References (51)

1. Alsina M. Fonseca R. Wilson E.F. Belle A.N. Gerbino E. Price-Troska T. Overton R.M. Ahmann G. Bruzek L.M. Adjei A.A. Kaufmann S.H. Wright J.J. Sullivan D. Djulbegovic B. Cantor A.B. Greipp P.R. Dalton W.S. Sebti S.M. ( 2004) The Farnesyltransferase Inhibitor Zarnestra is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumour survival pathways in patients with advanced multiple myeloma. Blood, 103, 3271 3277.
2. Beaupre D.M. Cepero E. Obeng E.A. Boise L.H. Lichtenheld M.G. ( 2004) R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Molecular Cancer Therapy, 3, 179 186.
3. Berenson J.R. ( 1999) Etiology of multiple myeloma: what's new. Seminars of Oncology, 26, 2 9.
4. Bezieau S. Devilder M.C. Avet-Loiseau H. Mellerin M.P. Puthier D. Pennarun E. Rapp M.J. Harousseau J.L. Moisan J.P. Bataille R. ( 2001) High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Human Mutations, 18, 212 224.
5. Bolick S.C. Landowski T.H. Boulware D. Oshiro M.M. Ohkanda J. Hamilton A.D. Sebti S.M. Dalton W.S. ( 2003) The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia, 17, 451 457.
6. Bradford M.M. ( 1976) A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248 254.
7. Chou T.C. Talalay P. ( 1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27 55.
8. Cortes J. Albitar M. Thomas D. Giles F. Kurzrock R. Thibault A. Rackoff W. Koller C. O'Brien S. Garcia-Manero G. Talpaz M. Kantarjian H. ( 2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 101, 1692 1697.
9. Crowder C. Kopantzev E. Williams K. Lengel C. Miki T. Rudikoff S. ( 2003) An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth. Oncogene, 22, 649 659.
10. van de Donk N.W. Kamphuis M.M. Lokhorst H.M. Bloem A.C. ( 2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 16, 1362 1371.
11. van de Donk N.W. Kamphuis M.M. Van Kessel B. Lokhorst H.M. Bloem A.C. ( 2003) Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood, 102, 3354 3362.
12. Doyle J.W. Kandutsch A.A. ( 1988) Requirement for mevalonate in cycling cells: quantitative and temporal aspects. Journal of Cell Physiology, 137, 133 140.
13. Durie B.G.M. Kyle R.A. Belch A. Bensinger W. Blade J. Boccadoro M. Child J.A. Comenzo R. Djulbegovic B. Fantl D. Gahrton G. Harousseau J.L. Hungria V. Joshua D. Ludwig H. Mehta J. Morales A.R. Morgan G. Nouel A. Oken M. Powles R. Roodman D. San Miguel J. Shimizu K. Singhal S. Sirohi B. Sonneveld P. Tricot G. Van Ness B. ( 2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 4, 379 398.
14. Ernst T.J. Gazdar A. Ritz J. Shipp M.A. ( 1988) Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood, 72, 1163 1167.
15. Gray-Bablin J. Rao S. Keyomarsi K. ( 1997) Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Research, 57, 604 609.
16. Greenwood J. Walters C.E. Pryce G. Kanuga N. Beraud E. Baker D. Adamson P. ( 2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB Journal, 17, 905 907.
17. Hallek M. Bergsagel P.L. Anderson K.C. ( 1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3 21.
18. Hernandez-Alcoceba R. del Peso R. Lacal J.C. ( 2000) The Ras family of GTPases in cancer cell invasion. Cellular and Molecular Life Sciences, 57, 65 76.
19. Holstein S.A. Wohlford-Lenane C.L. Hohl R.J. ( 2002) Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry, 41, 13698 13704.
20. James G. Goldstein J.L. Brown M.S. ( 1996) Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proceedings of the National Academy of Sciences of the United States of America, 93, 4454 4458.
21. Kalakonda N. Rothwell D.G. Scarffe J.H. Norton J.D. ( 2001) Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood, 98, 1555 1560.
22. Kastrinakis N.G. Gorgoulis V.G. Foukas P.G. Dimopoulos M.A. Kittas C. ( 2000) Molecular aspects of multiple myeloma. Annals of Oncology, 11, 1217 1228.
23. Keyomarsi K. Sandoval L. Band V. Pardee A.B. ( 1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Research, 51, 3602 3609.
24. Lerner E.C. Qian Y. Hamilton A.D. Sebti S.M. ( 1995) Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. Journal of Biological Chemistry, 270, 26770 26773.
25. Lerner E.C. Zhang T.T. Knowles D.B. Qian Y. Hamilton A.D. Sebti S.M. ( 1997) Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene, 15, 1283 1288.
26. Liu A. Du W. Liu J.P. Jessell T.M. Prendergast G.C. ( 2000) RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Molecular and Cellular Biology, 20, 6105 6113.
27. Lobell R.B. Omer C.A. Abrams M.T. Bhimnathwala H.G. Brucker M.J. Buser C.A. Davide J.P. de Solms S.J. Dinsmore C.J. Ellis-Hutchings M.S. Kral A.M. Liu D. Lumma W.C. Machotka S.V. Rands E. Williams T.M. Graham S.L. Hartman G.D. Oliff A.I. Heimbrook D.C. Kohl N.E. ( 2001) Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Research, 61, 8758 8768.
28. Mangues R. Corral T. Kohl N.E. Symmans W.F. Lu S. Malumbres M. Gibbs J.B. Oliff A. Pellicer A. ( 1998) Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Research, 58, 1253 1259.
29. Minden M.D. Dimitroulakos J. Nohynek D. Penn L.Z. ( 2001) Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leukemia and Lymphoma, 40, 659 662.
30. Morgan M.A. Dolp O. Reuter C.W.M. ( 2001) Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood, 97, 1823 1834.
31. Morgan M.A. Ganser A. Reuter C.W.M. ( 2003a) Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia, 17, 1482 1498.
32. Morgan M.A. Wegner J. Aydilek E. Ganser A. Reuter C.W.M. ( 2003b) Synergistic cytotoxic effects in myeloid leukemia cells upon co-treatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia, 17, 1508 1520.
33. Naderi S. Blomhoff R. Myklebust J. Smeland E.B. Erikstein B. Norum K.R. Blomhoff H.K. ( 1999) Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Experimental Cell Research, 252, 144 153.
34. Nagasu T. Yoshimatsu K. Rowell C. Lewis M.D. Garcia A.M. ( 1995) Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Research, 55, 5310 5314.
35. Ochiai N. Uchida R. Fuchida S. Okano A. Okamoto M. Ashihara E. Inaba T. Fujita N. Matsubara H. Shimazaki C. ( 2003) Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood, 102, 3349 3353.
36. Omer C.A. Chen Z. Diehl R.E. Conner M.W. Chen H.Y. Trumbauer M.E. Gopal-Truter S. Seeburger G. Bhimnathwala H. Abrams M.T. Davide J.P. Ellis M.S. Gibbs J.B. Greenberg I. Koblan K.S. Kral A.M. Liu D. Lobell R.B. Miller P.J. Mosser S.D. O'Neill T.J. Rands E. Schaber M.D. Senderak E.T. Oliff A. Kohl N.E. ( 2000) Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Research, 60, 2680 2688.
37. Podar K. Tai Y.T. Lin B.K. Narsimhan R.P. Sattler M. Kijima T. Salgia R. Gupta D. Chauhan D. Anderson K.C. ( 2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. Journal of Biological Chemistry, 277, 7875 7881.
38. Prendergast G.C. ( 2001) Actin' up: RhoB in cancer and apoptosis. Nature Reviews Cancer, 1, 162 168.
39. Qiang Y.W. Yao L. Tosato G. Rudikoff S. ( 2004) Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood, 103, 301 308.
40. Raftopoulou M. Hall A. ( 2004) Cell migration: Rho GTPases lead the way. Developmental Biology, 265, 23 32.
41. Reuter C.W.M. Morgan M.A. Bergmann L. ( 2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematological malignancies. Blood, 96, 1655 1669.
42. Rowell C.A. Kowalczyk J.J. Lewis M.D. Garcia A.M. ( 1997) Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. Journal of Biological Chemistry, 272, 14093 14097.
43. Shi Y. Gera J. Hu L. Hsu J.H. Bookstein R. Li W. Lichtenstein A. ( 2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Research, 62, 5027 5034.
44. Shipman C.M. Croucher P.I. Russell R.G. Helfrich M.H. Rogers M.J. ( 1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Research, 58, 5294 5297.
45. Stamatakis K. Cernuda-Morollon E. Hernandez-Perera O. Perez-Sala D. ( 2002) Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway. Journal of Biological Chemistry, 277, 49389 49396.
46. Sun J. Qian Y. Hamilton A.D. Sebti S.M. ( 1998) Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene, 16, 1467 1473.
47. Tobert J.A. ( 2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2, 517 526.
48. Ukomadu C. Dutta A. ( 2003) Inhibition of cdk2 activating phosphorylation by mevastatin. Journal of Biological Chemistry, 278, 4840 4846.
49. Vande Broek I. Asosingh K. Allegaert V. Leleu X. Facon T. Vanderkerken K. Van Camp B. Van Riet I. ( 2004) Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia, 18, 976 982.
50. Welsh C.F. ( 2004) Rho GTPases as key transducers of proliferative signals in g(1) cell cycle regulation. Breast Cancer Research and Treatment, 84, 33 42.
51. Whyte D.B. Kirschmeier P. Hockenberry T.N. Nunez-Oliva I. James L. Catino J.J. Bishop W.R. Pai J.K. ( 1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. Journal of Biological Chemistry, 272, 14459 14464.